CLINICAL ROLE -
Lung Cancer: Copayments and Behavior Following Erlotinib Formulary Tier Change
Moving erlotinib from formulary tier 3 to tier 2 resulted in lower copayments and higher treatment persistence among lung cancer patients.
Costs Associated With Second-Line Therapies for Lung Cancer
Erlotinib may confer an economic advantage for payers over docetaxel and pemetrexed for second-line treatment of lung cancer because of lower costs.
2 Clarke Drive Cranbury, NJ 08512